Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
Rojas
P
P
Instituto Nacional de Neurologia y Neurocirugia, Manuel Velasco Suárez, SSA, Laboratorio de Neuroquimica, México, D.F.
Altagracia
M
M
Kravsov
J
J
Rios
C
C
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000547:Amantadine / Q000627:therapeutic use*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D051379:Mice; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000517:prevention & control*
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000547:Amantadine; D004298:Dopamine; D006719:Homovanillic Acid